|
|
|
Insider
Information: |
Frates James M |
Relationship: |
|
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
318,827 |
|
Indirect Shares
|
184,010 |
|
|
Direct
Value |
$2,281,008 |
|
|
Indirect Value
|
$3,866,818 |
|
|
Total
Shares |
502,837 |
|
|
Total
Value |
$6,147,825 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alkermes Plc |
ALKS |
SVP, Alks Inc; CFO ALKS |
2020-05-14 |
91,828 |
2020-05-14 |
155,669 |
Premium* |
|
Sage Therapeutics, Inc. |
SAGE |
|
2021-06-16 |
1,035 |
2021-06-16 |
1,810 |
Premium* |
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2024-04-16 |
225,964 |
2024-04-16 |
26,531 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
262 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 10 of 11
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2019-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,625 |
47,316 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2019-02-26 |
4 |
D |
$33.92 |
$26,186 |
D/D |
(772) |
46,544 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2019-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,500 |
51,044 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2019-03-01 |
4 |
D |
$34.44 |
$45,564 |
D/D |
(1,323) |
49,721 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2019-05-06 |
4 |
OE |
$8.92 |
$71,360 |
D/D |
8,000 |
12,235 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2019-05-06 |
4 |
AS |
$162.22 |
$1,297,760 |
D/D |
(8,000) |
4,235 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2019-05-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,700 |
2,535 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2019-08-15 |
4 |
AS |
$160.58 |
$1,284,640 |
D/D |
(8,000) |
2,535 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2019-08-15 |
4 |
OE |
$28.35 |
$226,800 |
D/D |
8,000 |
10,535 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2019-09-13 |
4 |
OE |
$11.74 |
$234,800 |
D/D |
20,000 |
58,256 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,375 |
61,631 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-02-16 |
4 |
D |
$17.77 |
$20,826 |
D/D |
(1,172) |
60,459 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
63,459 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-02-17 |
4 |
D |
$17.77 |
$16,064 |
D/D |
(904) |
62,555 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,825 |
68,380 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-02-21 |
4 |
D |
$20.24 |
$34,651 |
D/D |
(1,712) |
66,668 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-03-01 |
4 |
D |
$20.84 |
$27,571 |
D/D |
(1,323) |
69,845 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,500 |
71,168 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2020-05-14 |
4 |
OE |
$11.74 |
$258,080 |
D/D |
21,983 |
91,828 |
0 |
- |
|
SAGE |
Sage Therapeutics, Inc. |
|
|
2021-06-16 |
4 |
B |
$55.10 |
$99,735 |
I/I |
1,810 |
1,810 |
0.01 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
31,667 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2022-01-06 |
4/A |
A |
$0.00 |
$0 |
I/I |
19,482 |
19,482 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2022-12-30 |
4 |
OE |
$6.88 |
$34,400 |
D/D |
5,000 |
36,667 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2023-01-06 |
4 |
S |
$36.08 |
$96,481 |
D/D |
(2,658) |
34,009 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2023-03-16 |
4/A |
A |
$0.00 |
$0 |
D/D |
21,667 |
55,676 |
0 |
- |
|
262 Records found
|
|
Page 10 of 11 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|